"Prasugrel Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.
| Descriptor ID |
D000068799
|
| MeSH Number(s) |
D02.886.778.315 D03.383.606.420 D03.383.903.315
|
| Concept/Terms |
LY 640315- LY 640315
- 640315, LY
- LY640315
- LY-640315
|
Below are MeSH descriptors whose meaning is more general than "Prasugrel Hydrochloride".
Below are MeSH descriptors whose meaning is more specific than "Prasugrel Hydrochloride".
This graph shows the total number of publications written about "Prasugrel Hydrochloride" by people in this website by year, and whether "Prasugrel Hydrochloride" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2016 | 4 | 0 | 4 |
| 2017 | 18 | 9 | 27 |
| 2018 | 15 | 11 | 26 |
| 2019 | 8 | 4 | 12 |
| 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Prasugrel Hydrochloride" by people in Profiles.
-
Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach. Drug Dev Res. 2021 04; 82(2):217-229.
-
Dual antiplatelet therapy in patients with acute coronary syndrome during the coronavirus disease of 2019 pandemia: the right choice at the right time. J Cardiovasc Med (Hagerstown). 2020 08; 21(8):535-537.
-
Efficacy and Safety of Clopidogrel, Prasugrel and Ticagrelor in ACS Patients Treated with PCI: A Propensity Score Analysis of the RENAMI and BleeMACS Registries. Am J Cardiovasc Drugs. 2020 Jun; 20(3):259-269.
-
Ticagrelor or Prasugrel in Acute Coronary Syndromes - The Winner Takes It All? N Engl J Med. 2019 10 17; 381(16):1582-1585.
-
Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial. EuroIntervention. 2019 08 09; 15(6):e513-e521.
-
Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. Eur Heart J. 2019 06 21; 40(24):1942-1951.
-
Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Vascul Pharmacol. 2019 09; 120:106564.
-
Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial. Can J Cardiol. 2019 10; 35(10):1377-1385.
-
Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease. Minerva Med. 2019 Oct; 110(5):410-418.
-
Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial. J Thromb Thrombolysis. 2019 Apr; 47(3):427-435.